

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Smoldering multiple myeloma: Rethinking the waiting game
- Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case










